- Home
- HMST vs IMMP Comparison
HMST vs IMMP Comparison
Compare HMST & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- IMMP
- Stock Information
- Founded
- HMST 1921
- IMMP 1987
- Country
- HMST United States
- IMMP Australia
- Employees
- HMST N/A
- IMMP N/A
- Industry
- HMST Major Banks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- IMMP Health Care
- Exchange
- HMST Nasdaq
- IMMP Nasdaq
- Market Cap
- HMST 211.3M
- IMMP 211.1M
- IPO Year
- HMST 2012
- IMMP N/A
- Fundamental
- Price
- HMST $13.03
- IMMP $1.88
- Analyst Decision
- HMST Hold
- IMMP Buy
- Analyst Count
- HMST 3
- IMMP 1
- Target Price
- HMST $14.17
- IMMP $7.00
- AVG Volume (30 Days)
- HMST 77.5K
- IMMP 726.6K
- Earning Date
- HMST 07-28-2025
- IMMP 02-27-2025
- Dividend Yield
- HMST N/A
- IMMP N/A
- EPS Growth
- HMST N/A
- IMMP N/A
- EPS
- HMST N/A
- IMMP N/A
- Revenue
- HMST $78,454,000.00
- IMMP $3,019,249.00
- Revenue This Year
- HMST $161.80
- IMMP $50.37
- Revenue Next Year
- HMST $8.90
- IMMP N/A
- P/E Ratio
- HMST N/A
- IMMP N/A
- Revenue Growth
- HMST N/A
- IMMP 24.11
- 52 Week Low
- HMST $8.09
- IMMP $1.32
- 52 Week High
- HMST $16.10
- IMMP $3.05
- Technical
- Relative Strength Index (RSI)
- HMST 65.81
- IMMP 49.87
- Support Level
- HMST $12.18
- IMMP $1.88
- Resistance Level
- HMST $12.76
- IMMP $2.05
- Average True Range (ATR)
- HMST 0.49
- IMMP 0.12
- MACD
- HMST 0.01
- IMMP -0.01
- Stochastic Oscillator
- HMST 92.42
- IMMP 22.22
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.